# A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

> **NCT05250973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 151 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05250973
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2025-05-30
- **Final completion:** 2026-10-22
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250973, "A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05250973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*